Pharmacogenetics of escitalopram and mental adaptation to cancer in palliative care: Report of 18 cases

Schillani, Giulia; Capozzo, Maria Anna; Era, Daniel; Vanna, Maurizio De; Grassi, Luigi; Conte, Maria Anna; Giraldi, Tullio

doi:10.1177/030089161109700317

Cited by 11 publications

(7 citation statements)

References 22 publications

(34 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hope and optimism have been negatively correlated to cancer patients' level of anxiety and depression [29,30]. In our study there was a parallel change in the levels of anxious and depressive symptoms and in the adaptation to cancer disease, with major reduction in the Helpless-Hopeless and Anxious Preoccupations dimensions and a significant increase of the Fighting Spirit component that we consider related to a better adherence to cancer treatment as described by others [31].…”

Section: Discussionsupporting

confidence: 79%

Mental Adjustment to Cancer: The Role of Anxious and Depressive Symptoms under Treatment

Fazio

Barberi

Caglioti

et al. 2013

Int J Psychiatry Med

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 79%

Mental Adjustment to Cancer: The Role of Anxious and Depressive Symptoms under Treatment

Fazio

Barberi

Caglioti

et al. 2013

Int J Psychiatry Med

View full text Add to dashboard Cite

show abstract

“…Nonetheless, beneficial outcomes in older patients have been established 39 . In addition, small cohort studies of selective serotonin RUI have shown significant improvement in depression and mental adaptation to cancer diagnosis 40 ,. 41 Use of antidepressants among cancer patients varies significantly and depends on cancer site, but we found slightly increased rates in comparison to previous US study that reported 19% antidepressant use in non‐specific cancer patients 42 .…”

Section: Discussionmentioning

confidence: 99%

Use of psychotropic drugs among older patients with bladder cancer in the United States

Jazzar

Bergerot²,

Shan

et al. 2021

Psycho-Oncology

View full text Add to dashboard Cite

Objective Older patients diagnosed with cancer are at increased risk of physical and emotional distress; however, prescription utilization patterns largely remain to be elucidated. Our objective was to comprehensively assess prescription patterns and predictors in older patients with bladder cancer. Methods A total of 10,516 older patients diagnosed with clinical stage T1–T4a, N0, M0 bladder urothelial carcinoma from 1 January 2008 to 31 December 2012 from the Surveillance, Epidemiology, and End Results (SEER)‐Medicare were analyzed. We used multivariable analysis to determine predictors associated with psychotropic prescription rates (one or more). Medication possession ratio (MPR) was used as an index to measure adherence in intervals of 3 months, 6 months, 1 year, and 2 years. Evaluation of psychotropic prescribing patterns and adherence across different drugs and demographic factors was done. Results Of the 10,516 older patients, 5621 (53%) were prescribed psychotropic drugs following cancer diagnosis. Overall, 3972 (38%) patients had previous psychotropic prescriptions prior to cancer diagnosis, and these patients were much more likely to receive a post‐cancer diagnosis prescription. Prescription rates for psychotropic medications were higher among patients with higher stage BC (p < 0.001). Gamma aminobutyric acid modulators/stimulators and serotonin reuptake inhibitors/stimulators were the highest prescribed psychotropic drugs in 21% of all patients. Adherence for all drugs was 32% at 3 months and continued to decrease over time. Conclusion Over half of the patients received psychotropic prescriptions within 2 years of their cancer diagnosis. Given the chronicity of psychiatric disorders with observed significantly low adherence to medications that warrants an emphasis on prolonged patient monitoring and further investigation.

show abstract

“…In the same context, Schillani et al reported that the use of SSRIs could be effective in palliative care of patients with cancer. It not only relieves depression symptoms but also improves mental adaptation to cancer (18).…”

Section: Discussionmentioning

confidence: 99%

Effectiveness of escitalopram in the reduction of pain, anxiety, and depression in patients with breast cancer: A randomized single-blind controlled trial

2021

ircmj

View full text Add to dashboard Cite

Background: Pain, anxiety, and depression are common but often neglected problems in patients with cancer. Objectives: Considering the importance and impact of anxiety and depression as common psychiatric symptoms in people with cancer, the present study aimed to assess the effectiveness of escitalopram in the reduction of pain, anxiety, and depression in patients with breast cancer. Methods: This single-blind controlled trial was conducted on 32 patients diagnosed with breast cancer who were referred for modified radical mastectomy (2018-2019). The intervention group received daily oral capsules containing 10 milligrams of escitalopram for four weeks, while the control group received placebo capsules containing starch on a daily basis. Hospital Anxiety and Depression Scale (HADS) and Visual Analogue Scale were administered to the patients at the commencement of the study and four weeks after the intervention. In addition, at baseline examination, personality factors were assessed by the NEO Five-Factor Inventory-3 questionnaire. Results: Based on the results, the scores of HADS anxiety, total HADS, and pain reduced after the intervention in the case group; however, the HADS depression score demonstrated a slight increase. A significant difference was observed between the case and control groups for HADS anxiety score after the intervention (P=0.01). The correlation of personality characteristics with HADS anxiety and depression subscales pointed out a significant negative correlation between the HADS depression score and conscientiousness (r=-0.40; P<0.05). Conclusion: Due to minor side effects of escitalopram, this drug is suggested to be used for the reduction of anxiety symptoms and pain intensity in patients with breast cancer.

show abstract

Pharmacogenetics of escitalopram and mental adaptation to cancer in palliative care: Report of 18 cases

Cited by 11 publications

References 22 publications

Mental Adjustment to Cancer: The Role of Anxious and Depressive Symptoms under Treatment

Mental Adjustment to Cancer: The Role of Anxious and Depressive Symptoms under Treatment

Use of psychotropic drugs among older patients with bladder cancer in the United States

Effectiveness of escitalopram in the reduction of pain, anxiety, and depression in patients with breast cancer: A randomized single-blind controlled trial

Contact Info

Product

Resources

About